Silexion Therapeutics Statistics
Total Valuation
SLXN has a market cap or net worth of $4.10 million. The enterprise value is $2.64 million.
Important Dates
The last earnings date was Thursday, November 14, 2024, before market open.
| Earnings Date | Nov 14, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
SLXN has 1.60 million shares outstanding.
| Current Share Class | 1.60M |
| Shares Outstanding | 1.60M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | 1.05% |
| Float | 1.29M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.46 |
| P/TBV Ratio | 4.93 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.85
| Current Ratio | 3.85 |
| Quick Ratio | 3.64 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -452.67 |
Financial Efficiency
Return on equity (ROE) is -116.66% and return on invested capital (ROIC) is -73.07%.
| Return on Equity (ROE) | -116.66% |
| Return on Assets (ROA) | -62.13% |
| Return on Capital (ROIC) | -73.07% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
| Beta (5Y) | -0.06 |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 2.72 |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 45.50 |
| Average Volume (20 Days) | 1,022,157 |
Short Selling Information
The latest short interest is 60,494, so 3.77% of the outstanding shares have been sold short.
| Short Interest | 60,494 |
| Short Previous Month | 322,582 |
| Short % of Shares Out | 3.77% |
| Short % of Float | 4.71% |
| Short Ratio (days to cover) | n/a |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -1.36M |
| Pretax Income | n/a |
| Net Income | -1.36M |
| EBITDA | -1.36M |
| EBIT | -1.36M |
| Earnings Per Share (EPS) | -$81.80 |
Full Income StatementBalance Sheet
| Cash & Cash Equivalents | 788,000 |
| Total Debt | n/a |
| Net Cash | 788,000 |
| Net Cash Per Share | $0.49 |
| Equity (Book Value) | 696,000 |
| Book Value Per Share | 4.67 |
| Working Capital | 687,000 |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$794,000 and capital expenditures -$5,000, giving a free cash flow of -$799,000.
| Operating Cash Flow | -794,000 |
| Capital Expenditures | -5,000 |
| Free Cash Flow | -799,000 |
| FCF Per Share | -$0.50 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
SLXN does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | -39.50% |
| FCF Yield | -23.29% |
Analyst Forecast
The average price target for SLXN is $9.00, which is 251.56% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $9.00 |
| Price Target Difference | 251.56% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 1 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsStock Splits
The last stock split was on November 29, 2024. It was a reverse split with a ratio of 0.1111111:1.
| Last Split Date | Nov 29, 2024 |
| Split Type | Reverse |
| Split Ratio | 0.1111111:1 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |